secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0000950170-23-004387
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma reports FY2022 net loss of $9.9M; cash $42.4M; strategic review ongoing
--------------------------------------------------------------------------------

- Net loss $9.9M ($0.69/share) vs $19.3M ($1.39/share) in 2021; operating expenses down to $10.6M from $19.3M.
- Cash and equivalents $42.4M at year-end; expected to fund operations through mid-2024.
- R&D expenses fell to $4.7M from $13.8M due to completion of rNAPc2 Phase 2b trial; restructuring charges of $0.8M in Q3 2022.
- Company engaged Ladenburg Thalmann to explore strategic alternatives including M&A; no timetable set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/abio-20230224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer